Compare Adaptive Biotechnologies Corp (ADPT) vs FirstEnergy Corp. (FE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs FirstEnergy Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $20.04 (market cap $3.33B), while FirstEnergy Corp. trades at $48.09 (market cap $27.99B). The key difference: FirstEnergy Corp. is far larger — about 8.4× Adaptive Biotechnologies Corp's market cap, and FirstEnergy Corp. pays a 3.84% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FE | |
|---|---|---|
Market Cap | $3.33B | $27.99B |
Sector | Health | Utilities |
52-Week High | $22.37 | $51.91 |
52-Week Low | $10.24 | $39.89 |
Enterprise Value | $3.19B | $56.00B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FirstEnergy (FE) trades at $48.39, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.25. The company reported revenue of $15.09 billion in 2025, with net income of $1.02 billion, and recent earnings have mostly beaten expectations. Positive news highlights growth from data center demand and a $36 billion investment plan for grid upgrades.
The outlook is supported by earnings visibility and strategic investments, but risks include regulatory uncertainty and high debt levels. With no sell ratings from analysts and a dividend payout scheduled, FE presents a steady utility investment with moderate upside potential balanced by sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
